Abstract:Rationale: Combinations of two or more therapeutic agents targeting different signaling pathways involved in tumor progression can have synergistic anticancer effects. However, combination chemotherapies are greatly limited by the different pharmacokinetics, tumor targeting, and cellular uptake capacities of the combined drugs. We have previously demonstrated the potential synergistic efficacy of paclitaxel (PTX) and the natural anti-angiogenic agent tetramethylpyrazine (TMP) for suppressing ovarian carcinoma growth. An efficient, facile, and smart nanosystem to deliver PTX and TMP simultaneously in vivo is greatly desired.Methods: We constructed a redox-sensitive nanosystem based on the amphiphilic PTX-ss-TMP conjugate, in which PTX and TMP are linked by a disulfide bond. We characterized the structure of the drug conjugate by 1H NMR and LC-MS, and then prepared PTX-ss-TMP NPs by a one-step nanoprecipitation method. We investigated the redox sensitivity, tumor-targeting ability, anticancer efficacy, and anti-angiogenesis activity of PTX-ss-TMP NPs in vitro and in vivo.Results: The amphiphilic PTX-ss-TMP conjugate readily self-assembled into stable nanoparticles in aqueous solution with a low critical association concentration of 1.35 µg/mL, well-defined spherical structure, small particle size (152 nm), high drug loading, redox-responsive drug release, high biocompatibility, and high storage stability. In cancer cells pretreated with GSH-OEt, PTX-ss-TMP NPs exhibited higher cytotoxicity, apoptosis rate, and cell-cycle arrest than monotherapy or combination therapy with free drugs, which was attributed to their improved cellular uptake and rapid intracellular drug release. Additionally, PTX-ss-TMP NPs also had a stronger anti-angiogenesis effect in HUVECs than free drug, which was mediated by VEGFR2-involved downstream signals. Finally, PTX-ss-TMP NPs showed tumor-specific accumulation and excellent antitumor activity in A2780 xenograft mice compared with free drug.Conclusions: These in vitro and in vivo results provide clear evidence that this redox-responsive carrier-free nanosystem with intrinsic amphiphilicity has great potential for combination cancer chemotherapy.

Paclitaxel-Tyroserleutide Conjugates Self-assembly into Nanocarrier for Drug Delivery

Amphiphilic conjugates for solubilization of paclitaxel as efficient drug carriers based on hyaluronic acid and cyclodextrins

Synthesis and Biological Evaluation of an Anticancer Drug Delivery System: Poly(l-γ-glutamyl-l-carbocisteine)-paclitaxel Nanoconjugate.

A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic

Paclitaxel Solubilized Nanoparticles Based on Binding Affinity for Efficient Drug Delivery

Superior Antitumor Effect of Self-Assembly Supramolecular Paclitaxel Nanoparticles

Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy

Engineering Self-Assembled Nanomedicines Composed of Clinically Approved Medicines for Enhanced Tumor Nanotherapy

Porphyrin Centered Paclitaxel Tetrameric Prodrug Nanoassemblies as Tumor‐Selective Theranostics for Synergized Breast Cancer Therapy

Ph-Responsive Stearic Acid-O-carboxymethyl Chitosan Assemblies As Carriers Delivering Small Molecular Drug for Chemotherapy

Superior Antitumor Effect of Extremely High Drug Loading Self-Assembled Paclitaxel Nanofibers

Self-assembly of Glutamic Acid Linked Paclitaxel Dimers into Nanoparticles for Chemotherapy

Multifunctional nanoparticles of paclitaxel and cyclodextrin-polypeptide conjugates with in vitro anticancer activity

Co-assembly of polymeric conjugates sensitizes neoadjuvant chemotherapy of Triple-Negative Breast Cancer with reduced systemic toxicity

Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy

Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel

Micelles via self-assembly of amphiphilic beta-cyclodextrin block copolymers as drug carrier for cancer therapy

Well-defined Polymer-Drug Conjugate Engineered with Redox and Ph-Sensitive Release Mechanism for Efficient Delivery of Paclitaxel.

Self-assembled Liposomes of Dual Paclitaxel-Phospholipid Prodrug for Anticancer Therapy.

Construction of polymer-paclitaxel conjugate linked via a disulfide bond.

Reduction-sensitive Dual Functional Nanomicelles for Improved Delivery of Paclitaxel.